Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$25.62 USD
+0.56 (2.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.64 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NRIX 25.62 +0.56(2.23%)
Will NRIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Other News for NRIX
Nurix Therapeutics management to meet with Oppenheimer
Nurix Therapeutics management to meet with Oppenheimer
Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Nurix Therapeutics transferred with an Outperform at Baird